학술논문
Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban - IRIS.
Document Type
Academic Journal
Author
Lavalle C; Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University, Rome, Italy.; Pierucci N; Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University, Rome, Italy - npierucci@gmail.com.; Mariani MV; Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University, Rome, Italy.; Piro A; Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University, Rome, Italy.; Borrelli A; Division of Cardiology, Policlinico Casilino, Rome, Italy.; Grimaldi M; Department of Cardiology, Ospedale Generale Regionale F. Miulli, Acquaviva delle Fonti, Bari, Italy.; Rossillo A; Department of Cardiology, San Bortolo Hospital, Vicenza, Italy.; Notarstefano P; Department Cardiology, San Donato Hospital, Arezzo, Italy.; Compagnucci P; Department of Biomedical Science and Public Health, Clinic of Cardiology and Arrhythmology, Ospedali Riuniti University Hospital, Marche Polytechnic University, Ancona, Italy.; Dello Russo A; Department of Biomedical Science and Public Health, Clinic of Cardiology and Arrhythmology, Ospedali Riuniti University Hospital, Marche Polytechnic University, Ancona, Italy.; Perna F; Department of Cardiovascular Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.; Pelargonio G; Department of Cardiovascular Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.; LA Fazia VM; St. David's Medical Center, Texas Cardiac Arrhythmia Institute, Austin, TX, USA.; Della Rocca DG; Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Heart Rhythm Management Center, University Hospital of Brussels, Vrije Universiteit Brussel, Brussels, Belgium.; Miraldi F; Department of Cardio-Thoracic-Vascular and Organ Transplantation Surgery, Umberto I Polyclinic Hospital, Rome, Italy.; Forleo GB; Unit of Cardiology, ASST-Fatebenefratelli Sacco, Milan, Italy.
Source
Publisher: Minerva medica Country of Publication: Italy NLM ID: 101776555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2724-5772 (Electronic) Linking ISSN: 27245683 NLM ISO Abbreviation: Minerva Cardiol Angiol Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Catheter ablation (CA) of atrial fibrillation is routinely used to obtain rhythm control. Evidence suggest that catheter ablation should be done during uninterrupted oral anticoagulation.
Methods: Italian Registry in the setting of atrial fibrillation ablation with rivaroxaban (IRIS) is an Italian multicenter, non-interventional, prospective study which enrolled 250 consecutive atrial fibrillation patients eligible for catheter ablation on rivaroxaban. The decision for rivaroxaban management was left to the physician: uninterrupted or shortly interrupted prior to Catheter ablation. Patients received a follow-up visit at 1 month and 12 months after the procedure.
Results: The primary outcome, represented by all-cause death and systemic embolism at 1 month and 12 months was characterized by one transient ischemic attack and one myocardial infarction in the first 30 days. Both events happened in patients with shortly interrupted strategy (P=0.147), and both in patients who underwent radiofrequency ablation (P=0.737). In the primary safety outcome represented by major bleeding we did not register any event in the 12-month follow-up. The secondary outcome constituted by minor bleeding registered 1 event, after the first 30 days since CA.
Conclusions: IRIS is the biggest real-life data registry regarding CA ablation on rivaroxaban in Italian setting, proving the safety and efficacy of rivaroxaban.
Methods: Italian Registry in the setting of atrial fibrillation ablation with rivaroxaban (IRIS) is an Italian multicenter, non-interventional, prospective study which enrolled 250 consecutive atrial fibrillation patients eligible for catheter ablation on rivaroxaban. The decision for rivaroxaban management was left to the physician: uninterrupted or shortly interrupted prior to Catheter ablation. Patients received a follow-up visit at 1 month and 12 months after the procedure.
Results: The primary outcome, represented by all-cause death and systemic embolism at 1 month and 12 months was characterized by one transient ischemic attack and one myocardial infarction in the first 30 days. Both events happened in patients with shortly interrupted strategy (P=0.147), and both in patients who underwent radiofrequency ablation (P=0.737). In the primary safety outcome represented by major bleeding we did not register any event in the 12-month follow-up. The secondary outcome constituted by minor bleeding registered 1 event, after the first 30 days since CA.
Conclusions: IRIS is the biggest real-life data registry regarding CA ablation on rivaroxaban in Italian setting, proving the safety and efficacy of rivaroxaban.